microRNA based prognostic biomarkers in pancreatic Cancer
| Autor: | Shixiang Guo, Huaizhi Wang, Jingfang Ju, Andrew Fesler |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pancreatic ductal adenocarcinoma endocrine system diseases medicine.medical_treatment Clinical Biochemistry Resistance Review 03 medical and health sciences 0302 clinical medicine Pancreatic cancer microRNA Overall survival medicine Chemotherapy Epigenetics miRNA business.industry Biochemistry (medical) lcsh:RM1-950 Therapeutic resistance medicine.disease Prognosis Gemcitabine digestive system diseases 030104 developmental biology lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis Cancer research Molecular Medicine business Biomarkers medicine.drug |
| Zdroj: | Biomarker Research, Vol 6, Iss 1, Pp 1-5 (2018) Biomarker Research |
| ISSN: | 2050-7771 |
| Popis: | Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink